Dr. Lal Path Labs Ltd. has informed the Exchange about acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited ( SDCPL ) from its existing Shareholders. Post acquisition, SDCPL shall become a Wholly Owned Subsidiary of the Company.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.8 pts more than Nifty Smallcap 250 and 12.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported strong FY26 results with consolidated revenue of Rs 27,629 million (up 12% YoY) and profit after tax of Rs 5,098 million (up 4% YoY). The Board approved acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary. Additionally, the company will incorporate a new wholly-owned subsidiary in Dubai, UAE (Dr. Lal PathLabs FZCO). For shareholders, a final dividend of Rs 4 per share is recommended (total FY26 dividend: Rs 20.5 per share). Key director re-appointments include Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta for 5-year terms. EPS for FY26 stands at Rs 30.24.
The acquisition of SDCPL expands Dr. Lal PathLabs' diagnostic network, while the Dubai subsidiary marks international expansion. Strong 12% revenue growth and total dividend of Rs 20.5 per share are positive signals for shareholders.